Las Vegas, United States
CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) will host a conference call for investors and other interested parties on Thursday, July 19, 2007 at 11:00 a.m. EST/8:00 a.m. PST to discuss recently announced plans for a Phase II clinical trial for the treatment of severe coronary heart disease. Company executives will also conduct a question and answer session following prepared remarks.
Individuals interested in listening to the conference call may do so by dialing (888) 927-9756 for domestic callers or (706) 679-0879 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 for domestic callers, or (706) 645-9291 for international callers, and entering reservation code 6349682.
The live conference call will also be available via the Internet on the Investor Relations section of the Company's Web site at www.cvbt.com. A slide presentation that accompanies management's remarks will also be available on the Investor section of the site. A recording of the call will be available on the Company's Web site for 30 days following the completion of the call.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates with human FGF-1 as their active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has three clinical trials underway with drug candidates to treat the following medical indications: severe Coronary Heart Disease (CVBT-141A), dermal wound healing in diabetics (CVBT-141B), and Peripheral Arterial Disease (CVBT-141C).
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.
Source: Business Wire (Business Wire India)